메뉴 건너뛰기




Volumn 10, Issue , 2016, Pages 745-755

Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways

Author keywords

Apoptosis; HIF1 ; MDM2; MTOR; P53; Renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDOLE DERIVATIVE; MI 319; PROTEIN KINASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; SPIRO COMPOUND; TARGET OF RAPAMYCIN KINASE;

EID: 84959537613     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S88779     Document Type: Article
Times cited : (11)

References (56)
  • 2
    • 0028072991 scopus 로고
    • Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
    • Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994;91(21):9700–9704.
    • (1994) Proc Natl Acad Sci U S A , vol.91 , Issue.21 , pp. 9700-9704
    • Herman, J.G.1    Latif, F.2    Weng, Y.3
  • 4
    • 54549113030 scopus 로고    scopus 로고
    • The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer
    • 2sensing and cancer. Nat Rev Cancer. 2008;8(11):865–873.
    • (2008) Nat Rev Cancer , vol.8 , Issue.11 , pp. 865-873
    • Kaelin, W.G.1
  • 5
    • 84859372195 scopus 로고    scopus 로고
    • EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma
    • Dorđević G, Matušan Ilijaš K, Hadžisejdić I, Maričić A, Grahovac B, Jonjić N. EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma. J Biomed Sci. 2012;19:40.
    • (2012) J Biomed Sci , vol.19
    • Dorđević, G.1    Matušan Ilijaš, K.2    Hadžisejdić, I.3    Maričić, A.4    Grahovac, B.5    Jonjić, N.6
  • 6
    • 77952545672 scopus 로고    scopus 로고
    • TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe
    • Szymańska K, Moore LE, Rothman N, et al. TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett. 2010;293(1):92–98.
    • (2010) Cancer Lett , vol.293 , Issue.1 , pp. 92-98
    • Szymańska, K.1    Moore, L.E.2    Rothman, N.3
  • 7
    • 4043171462 scopus 로고    scopus 로고
    • Upstream and downstream of mTOR
    • Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–1945.
    • (2004) Genes Dev , vol.18 , Issue.16 , pp. 1926-1945
    • Hay, N.1    Sonenberg, N.2
  • 8
    • 84921776079 scopus 로고    scopus 로고
    • RNA-seq reveals aurora kinase-driven mTOR Pathway activation in patients with sarcomatoid metastatic renal cell carcinoma
    • Pal SK, He M, Tong T, et al. RNA-seq reveals aurora kinase-driven mTOR Pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res. 2015;13(1):130–137.
    • (2015) Mol Cancer Res , vol.13 , Issue.1 , pp. 130-137
    • Pal, S.K.1    He, M.2    Tong, T.3
  • 9
    • 84907468719 scopus 로고    scopus 로고
    • MTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma
    • Bailey ST, Zhou B, Damrauer JS, et al. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. PloS One. 2014;9(9):e104413.
    • (2014) Plos One , vol.9 , Issue.9
    • Bailey, S.T.1    Zhou, B.2    Damrauer, J.S.3
  • 10
    • 84892915652 scopus 로고    scopus 로고
    • Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma
    • Okazaki H, Matsunaga N, Fujioka T, et al. Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma. Cancer Res. 2014;74(2):543–551.
    • (2014) Cancer Res , vol.74 , Issue.2 , pp. 543-551
    • Okazaki, H.1    Matsunaga, N.2    Fujioka, T.3
  • 11
    • 34347220473 scopus 로고    scopus 로고
    • Defining the role of mTOR in cancer
    • Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9–22.
    • (2007) Cancer Cell , vol.12 , Issue.1 , pp. 9-22
    • Guertin, D.A.1    Sabatini, D.M.2
  • 12
    • 84855322629 scopus 로고    scopus 로고
    • MTOR activates hypoxia-inducible factor-1α and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia
    • Chen H, Xiong T, Qu Y, Zhao F, Ferriero D, Mu D. mTOR activates hypoxia-inducible factor-1α and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia. Neurosci Lett. 2012;507(2):118–123.
    • (2012) Neurosci Lett , vol.507 , Issue.2 , pp. 118-123
    • Chen, H.1    Xiong, T.2    Qu, Y.3    Zhao, F.4    Ferriero, D.5    Mu, D.6
  • 13
    • 34547134517 scopus 로고    scopus 로고
    • Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (MTOR) via an mTOR signaling motif
    • Land SC, Tee AR. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007;282(28):20534–20543.
    • (2007) J Biol Chem , vol.282 , Issue.28 , pp. 20534-20543
    • Land, S.C.1    Tee, A.R.2
  • 14
    • 30044432434 scopus 로고    scopus 로고
    • Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
    • Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12(1):122–127.
    • (2006) Nat Med , vol.12 , Issue.1 , pp. 122-127
    • Thomas, G.V.1    Tran, C.2    Mellinghoff, I.K.3
  • 15
    • 84865856500 scopus 로고    scopus 로고
    • Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia
    • Karar J, Cerniglia GJ, Lindsten T, Koumenis C, Maity A. Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther. 2012;13(11):1102–1111.
    • (2012) Cancer Biol Ther , vol.13 , Issue.11 , pp. 1102-1111
    • Karar, J.1    Cerniglia, G.J.2    Lindsten, T.3    Koumenis, C.4    Maity, A.5
  • 16
    • 84899538303 scopus 로고    scopus 로고
    • Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: Progression-free survival lasting for over 3 years, a case report and review of the literature
    • Daste A, Gross-Goupil M, Roca S, Bernhard JC, Ravaud A. Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature. Target Oncol. 2014;9(1):81–84.
    • (2014) Target Oncol , vol.9 , Issue.1 , pp. 81-84
    • Daste, A.1    Gross-Goupil, M.2    Roca, S.3    Bernhard, J.C.4    Ravaud, A.5
  • 17
    • 84898011066 scopus 로고    scopus 로고
    • Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor
    • Santoni M, Berardi R, Amantini C, et al. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer. 2014;134(12):2772–2777.
    • (2014) Int J Cancer , vol.134 , Issue.12 , pp. 2772-2777
    • Santoni, M.1    Berardi, R.2    Amantini, C.3
  • 18
    • 0842304369 scopus 로고    scopus 로고
    • Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
    • Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004;100(4):657–666.
    • (2004) Cancer , vol.100 , Issue.4 , pp. 657-666
    • Panwalkar, A.1    Verstovsek, S.2    Giles, F.J.3
  • 19
    • 65549167833 scopus 로고    scopus 로고
    • Targeting the mTOR signaling network for cancer therapy
    • Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27(13):2278–2287.
    • (2009) J Clin Oncol , vol.27 , Issue.13 , pp. 2278-2287
    • Meric-Bernstam, F.1    Gonzalez-Angulo, A.M.2
  • 20
    • 0041802820 scopus 로고    scopus 로고
    • Targeting mTOR signaling for cancer therapy
    • Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 2003;3(4):371–377.
    • (2003) Curr Opin Pharmacol , vol.3 , Issue.4 , pp. 371-377
    • Huang, S.1    Houghton, P.J.2
  • 21
    • 1542398693 scopus 로고    scopus 로고
    • Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    • Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–918.
    • (2004) J Clin Oncol , vol.22 , Issue.5 , pp. 909-918
    • Atkins, M.B.1    Hidalgo, M.2    Stadler, W.M.3
  • 22
    • 1542327671 scopus 로고    scopus 로고
    • Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
    • Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004;101(9):3130–3135.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , Issue.9 , pp. 3130-3135
    • Mohi, M.G.1    Boulton, C.2    Gu, T.L.3
  • 23
    • 6044259204 scopus 로고    scopus 로고
    • Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells
    • Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004;10(20):7031–7042.
    • (2004) Clin Cancer Res , vol.10 , Issue.20 , pp. 7031-7042
    • Mondesire, W.H.1    Jian, W.2    Zhang, H.3
  • 24
    • 84880489175 scopus 로고    scopus 로고
    • Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells
    • Fei SJ, Zhang XC, Dong S, et al. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells. PloS One. 2013;8(7):e69104.
    • (2013) Plos One , vol.8 , Issue.7
    • Fei, S.J.1    Zhang, X.C.2    Dong, S.3
  • 25
    • 84883328678 scopus 로고    scopus 로고
    • Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma
    • Ku BM, Kim DS, Kim KH, et al. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J. 2013;27(9):3487–3495.
    • (2013) FASEB J , vol.27 , Issue.9 , pp. 3487-3495
    • Ku, B.M.1    Kim, D.S.2    Kim, K.H.3
  • 26
    • 14644428498 scopus 로고    scopus 로고
    • The relationship of expression of Bcl-2, p53, and proliferating cell nuclear antigen (PCNA) to cell proliferation and apoptosis in renal cell carcinoma
    • Zhu Z, Xing S, Cheng P, et al. The relationship of expression of Bcl-2, p53, and proliferating cell nuclear antigen (PCNA) to cell proliferation and apoptosis in renal cell carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2004;24(4):354–357.
    • (2004) J Huazhong Univ Sci Technolog Med Sci , vol.24 , Issue.4 , pp. 354-357
    • Zhu, Z.1    Xing, S.2    Cheng, P.3
  • 27
    • 0031907378 scopus 로고    scopus 로고
    • P53 Modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line
    • Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. p53 Modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. Int J Oncol. 1998;12(2):469–473.
    • (1998) Int J Oncol , vol.12 , Issue.2 , pp. 469-473
    • Miyake, H.1    Hara, I.2    Gohji, K.3    Arakawa, S.4    Kamidono, S.5
  • 28
    • 0034704923 scopus 로고    scopus 로고
    • The loss of mdm2 induces p53-mediated apoptosis
    • de Rozieres S, Maya R, Oren M, Lozano G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene. 2000;19(13):1691–1697.
    • (2000) Oncogene , vol.19 , Issue.13 , pp. 1691-1697
    • De Rozieres, S.1    Maya, R.2    Oren, M.3    Lozano, G.4
  • 29
    • 0032185124 scopus 로고    scopus 로고
    • Kung AL, et al. P300/MDM2 complexes participate in MDM2-mediated p53 degradation
    • Grossman SR, Perez M, Kung AL, et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell. 1998;2(4):405–415.
    • (1998) Mol Cell , vol.2 , Issue.4 , pp. 405-415
    • Grossman, S.R.1    Perez, M.2
  • 30
    • 0026649648 scopus 로고
    • The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
    • Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237–1245.
    • (1992) Cell , vol.69 , Issue.7 , pp. 1237-1245
    • Momand, J.1    Zambetti, G.P.2    Olson, D.C.3    George, D.4    Levine, A.J.5
  • 32
    • 78049305999 scopus 로고    scopus 로고
    • MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma
    • Jin L, Tabe Y, Kojima K, et al. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 2010;299(2):161–170.
    • (2010) Cancer Lett , vol.299 , Issue.2 , pp. 161-170
    • Jin, L.1    Tabe, Y.2    Kojima, K.3
  • 33
    • 84873082565 scopus 로고    scopus 로고
    • Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles
    • Yu H, Zou Y, Jiang L, et al. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials. 2013;34(11):2738–2747.
    • (2013) Biomaterials , vol.34 , Issue.11 , pp. 2738-2747
    • Yu, H.1    Zou, Y.2    Jiang, L.3
  • 34
    • 84873079604 scopus 로고    scopus 로고
    • Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells
    • Mir R, Tortosa A, Martinez-Soler F, et al. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Int J Cancer. 2013;132(7):1525–1536.
    • (2013) Int J Cancer , vol.132 , Issue.7 , pp. 1525-1536
    • Mir, R.1    Tortosa, A.2    Martinez-Soler, F.3
  • 35
    • 79960087105 scopus 로고    scopus 로고
    • The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis
    • Kong L, Yuan Q, Zhu H, et al. The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. Biomaterials. 2011;32(27):6515–6522.
    • (2011) Biomaterials , vol.32 , Issue.27 , pp. 6515-6522
    • Kong, L.1    Yuan, Q.2    Zhu, H.3
  • 36
    • 76249112073 scopus 로고    scopus 로고
    • P53 and MDM2 in renal cell carcinoma: Biomarkers for disease progression and future therapeutic targets?
    • Noon AP, Vlatkovic N, Polanski R, et al. P53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer. 2010;116(4):780–790.
    • (2010) Cancer , vol.116 , Issue.4 , pp. 780-790
    • Noon, A.P.1    Vlatkovic, N.2    Polanski, R.3
  • 37
    • 0036129145 scopus 로고    scopus 로고
    • Clinical significance of p53, mdm2, and Bcl-2 proteins in renal cell carcinoma
    • Uchida T, Gao JP, Wang C, et al. Clinical significance of p53, mdm2, and Bcl-2 proteins in renal cell carcinoma. Urology. 2002;59(4): 615–620.
    • (2002) Urology , vol.59 , Issue.4 , pp. 615-620
    • Uchida, T.1    Gao, J.P.2    Wang, C.3
  • 38
    • 0034026143 scopus 로고    scopus 로고
    • Mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: Comparison with p53 overexpression and clinicopathological parameters
    • Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. Mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res. 2000;6(5):1840–1844.
    • (2000) Clin Cancer Res , vol.6 , Issue.5 , pp. 1840-1844
    • Haitel, A.1    Wiener, H.G.2    Baethge, U.3    Marberger, M.4    Susani, M.5
  • 39
    • 51649098950 scopus 로고    scopus 로고
    • The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
    • Kojima K, Shimanuki M, Shikami M, et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia. 2008;22(9):1728–1736.
    • (2008) Leukemia , vol.22 , Issue.9 , pp. 1728-1736
    • Kojima, K.1    Shimanuki, M.2    Shikami, M.3
  • 40
    • 72549094296 scopus 로고    scopus 로고
    • An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
    • Mohammad RM, Wu J, Azmi AS, et al. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer. 2009;8:115.
    • (2009) Mol Cancer , vol.8
    • Mohammad, R.M.1    Wu, J.2    Azmi, A.S.3
  • 41
    • 34547220487 scopus 로고    scopus 로고
    • MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma
    • Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007;13(14):4123–4129.
    • (2007) Clin Cancer Res , vol.13 , Issue.14 , pp. 4123-4129
    • Hirata, H.1    Hinoda, Y.2    Kikuno, N.3
  • 42
    • 33748254960 scopus 로고    scopus 로고
    • Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas
    • Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci. 2006;36(3):283–293.
    • (2006) Ann Clin Lab Sci , vol.36 , Issue.3 , pp. 283-293
    • Lin, F.1    Zhang, P.L.2    Yang, X.J.3    Prichard, J.W.4    Lun, M.5    Brown, R.E.6
  • 43
    • 84911387339 scopus 로고    scopus 로고
    • Fulda S. Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling
    • Fulda S. Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling. Mitochondrion. 2014;19 Pt A:85–87.
    • (2014) Mitochondrion , vol.19 , pp. 85-87
  • 44
    • 0034145215 scopus 로고    scopus 로고
    • Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (Review)
    • Minet E, Michel G, Remacle J, Michiels C. Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review). Int J Mol Med. 2000;5(3):253–259.
    • (2000) Int J Mol Med , vol.5 , Issue.3 , pp. 253-259
    • Minet, E.1    Michel, G.2    Remacle, J.3    Michiels, C.4
  • 45
    • 71549134278 scopus 로고    scopus 로고
    • Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells
    • Kao CL, Hsu HS, Chen HW, Cheng TH. Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells. Cancer Lett. 2009;286(2):250–259.
    • (2009) Cancer Lett , vol.286 , Issue.2 , pp. 250-259
    • Kao, C.L.1    Hsu, H.S.2    Chen, H.W.3    Cheng, T.H.4
  • 46
    • 20444363122 scopus 로고    scopus 로고
    • The coordinate regulation of the p53 and mTOR pathways in cells
    • Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A. 2005;102(23):8204–8209.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , Issue.23 , pp. 8204-8209
    • Feng, Z.1    Zhang, H.2    Levine, A.J.3    Jin, S.4
  • 47
    • 77954310492 scopus 로고    scopus 로고
    • The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein
    • Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 2010;20(7):427–434.
    • (2010) Trends Cell Biol , vol.20 , Issue.7 , pp. 427-434
    • Feng, Z.1    Levine, A.J.2
  • 48
    • 84925659251 scopus 로고    scopus 로고
    • Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma
    • von Roemeling CA, Marlow LA, Kennedy WP, Kennedy GT, Copland JA, Menefee ME. Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma. Am J Cancer Res. 2013;3(4):390–401.
    • (2013) Am J Cancer Res , vol.3 , Issue.4 , pp. 390-401
    • Von Roemeling, C.A.1    Marlow, L.A.2    Kennedy, W.P.3    Kennedy, G.T.4    Copland, J.A.5    Menefee, M.E.6
  • 49
    • 79960683561 scopus 로고    scopus 로고
    • Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
    • Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer. 2011;10:90.
    • (2011) Mol Cancer , vol.10
    • Roulin, D.1    Waselle, L.2    Dormond-Meuwly, A.3    Dufour, M.4    Demartines, N.5    Dormond, O.6
  • 50
    • 84856739876 scopus 로고    scopus 로고
    • Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: Combined mTOR and AKT inhibitor therapy
    • Holland WS, Tepper CG, Pietri JE, et al. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012;69(1):185–194.
    • (2012) Cancer Chemother Pharmacol , vol.69 , Issue.1 , pp. 185-194
    • Holland, W.S.1    Tepper, C.G.2    Pietri, J.E.3
  • 51
    • 73649094752 scopus 로고    scopus 로고
    • PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2
    • Choy MK, Movassagh M, Bennett MR, Foo RS. PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2. J Cell Physiol. 2010;222(3):635–639.
    • (2010) J Cell Physiol , vol.222 , Issue.3 , pp. 635-639
    • Choy, M.K.1    Movassagh, M.2    Bennett, M.R.3    Foo, R.S.4
  • 52
    • 68849093989 scopus 로고    scopus 로고
    • Tumour suppression by p53: The importance of apoptosis and cellular senescence
    • Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathology. 2009;219(1):3–15.
    • (2009) J Pathology , vol.219 , Issue.1 , pp. 3-15
    • Zuckerman, V.1    Wolyniec, K.2    Sionov, R.V.3    Haupt, S.4    Haupt, Y.5
  • 53
    • 84894079832 scopus 로고    scopus 로고
    • Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
    • Santoni M, Pantano F, Amantini C, et al. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. Biochim Biophys Acta. 2014;1845(2):221–231.
    • (2014) Biochim Biophys Acta , vol.1845 , Issue.2 , pp. 221-231
    • Santoni, M.1    Pantano, F.2    Amantini, C.3
  • 54
    • 22044438985 scopus 로고    scopus 로고
    • Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma
    • Gemmill RM, Zhou M, Costa L, Korch C, Bukowski RM, Drabkin HA. Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer. 2005;92(12):2266–2277.
    • (2005) Br J Cancer , vol.92 , Issue.12 , pp. 2266-2277
    • Gemmill, R.M.1    Zhou, M.2    Costa, L.3    Korch, C.4    Bukowski, R.M.5    Drabkin, H.A.6
  • 56
    • 44649141966 scopus 로고    scopus 로고
    • Regulation of autophagy by cytoplasmic p53
    • Tasdemir E, Maiuri MC, Galluzzi L, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol. 2008;10(6):676–687.
    • (2008) Nat Cell Biol , vol.10 , Issue.6 , pp. 676-687
    • Tasdemir, E.1    Maiuri, M.C.2    Galluzzi, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.